Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Ergosterol Synthesis Inhibitors Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.
The growth of the market can be attributed to the increasing prevalence of fungal infections, especially in the tropical and sub-tropical regions in the world. Ergosterol is a compound present in the walls of fungal cells, which is essential for the viability of all fungi. Ergosterol synthesis inhibitors hamper the biosynthesis of this compound, which kills the fungi colony, therefore treating the infection. The demand for ergosterol synthesis inhibitors is estimated to grow on the back of its efficiency in alleviating fungal infections, including jock itch, ringworm, yeast infection, and dandruff. Moreover, lack of proper sanitization facilities and cleanliness in major parts of the world, is further expected to boost the market growth.

Ergosterol Synthesis Inhibitors Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Fungal Infections
- Lack of Proper Sanitization in Developing Nations
Challenges
- Risk of Hepatotoxicity Caused by the Inhibitors
- Availability of Generic Drugs in the Market
Ergosterol Synthesis Inhibitors Market: Key Insights
Ergosterol Synthesis Inhibitors Segmentation
The global ergosterol synthesis inhibitors market is segmented by route of administration into topical, oral, and others, out of which, the topical segment is anticipated to hold the largest share in the market during the forecast period on account of ease of application, and higher effectiveness, as it directly targets the infection. On the basis of end-user, the market is segmented into pharmacy, hospital, and others. Out of these, the pharmacy segment is estimated to hold a notable share over the forecast period owing to the growing demand for over-the-counter inhibitors to cure fungal infections.
Our in-depth analysis of the global ergosterol synthesis inhibitors market includes the following segments
By Drug Type |
|
By Route of Administration |
|
By End-User
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportErgosterol Synthesis Inhibitors Industry - Regional Synopsis
APAC Market Statistics
Regionally, the global ergosterol synthesis inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is set to dominate majority revenue share by 2037, on the back of rising prevalence of fungal infections, in tropical countries, such as, Indonesia, Thailand, and India. India witnessed 5 to 10 cases of fungal infection per 1,000 individuals, in 2019. The share in Thailand amounted 12-15 cases per 1000 individuals. Moreover, growing medical infrastructure and improving public healthcare system, backed by economic growth in the region, is estimated to boost the market growth.
Latin America Market Analysis
The ergosterol synthesis inhibitors market in the Latin America region is estimated to witness noteworthy growth over the forecast period, owing to the rising incidences of infections backed by the climatic conditions favorable for fungal infections, along with unavailability of proper sanitization and cleanliness is estimated to boost the market growth.

Companies Dominating the Ergosterol Synthesis Inhibitors Landscape
- SCYNEXIS, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Novartis AG
- Kramer Laboratories, Inc.
- Abbott Laboratories
- Bayer AG
- GlaxoSmithKline plc.
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc.
- Astellas Pharma Inc.
In the News
- April 30, 2021: SCYNEXIS announced the positive clinical outcomes of the investigational drug ibrexafungerp for vaginal yeast infections.
- March 22, 2021: Glenmark Pharmaceuticals Limited to join hands with Bausch Health Companies, Inc. for the market in Canada
Author Credits: Radhika Pawar
- Report ID: 3111
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT